Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Second Infusion of FAP-targeted CAR-DC in End-stage Dilated Cardiomyopathy
NCT07516288Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FAP CAR-T cell therapy in dilated cardiomyopathy (DCM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Dose-limiting toxicity at 14 days and Treatment-emergent adverse events at 14 days. Started May 2026; status: recruiting.
02
Drugs
FAP CAR-T cell therapy
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT07516288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516288.